Sharescart Research Club logo
Products
Research
Tools
About
  • Home
  • /
  • Meghmani Finechem
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel

Epigral

WEBSITE BSE:543332 NSE: EPIGRAL Inc. Year: 2007 Industry: Chemicals My Bucket: Add Stock

₹1201.1 -7 | 0.6%

Last updated: 15:56

Consolidated Standalone

Last updated: 15:56

Epigral Overview

Meghmani Finechem Ltd manufactures and sells chlor-alkali and its derivatives in India. The enterprise offers caustic soda, chlorine, hydrogen, caustic potash, chloromethanes, and hydrogen peroxide. It serves alumina, textile, crop protection, refineries, pharmaceutical, paper and pulp, dyes and pigments, cleaning soap and detergent, refrigerant gases, and different industries. The business enterprise was established in 2007 and is based totally in Ahmedabad, India.

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Epigral Key Financials

Market Cap ₹5181 Cr.

Stock P/E 14.5

P/B 2.4

Current Price ₹1201.1

Book Value ₹ 496.1

Face Value 10

52W High ₹2114.3

Dividend Yield 0.5%

52W Low ₹ 806.2

Edit Ratio

Epigral Share Price

₹ | |

Volume
Price

Epigral Quarterly Price

Quarterly Monthly
Show Value Show %

Epigral Peer Comparison

Epigral Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 478 472 525 651 626 645 628 607 587 597
Other Income 1 2 2 2 6 4 3 8 2 6
Total Income 479 474 526 654 632 649 631 615 589 603
Total Expenditure 370 349 369 475 448 463 454 443 455 494
Operating Profit 109 125 157 179 184 186 177 172 134 108
Interest 21 20 14 14 27 -0 12 23 22 11
Depreciation 32 31 30 33 32 33 34 42 42 43
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 56 74 113 131 124 154 131 107 70 55
Provision for Tax 18 25 36 45 44 50 44 -54 18 15
Profit After Tax 38 49 77 86 81 104 87 160 52 39
Adjustments -0 -0 1 -0 1 0 0 0 -0 -0
Profit After Adjustments 38 49 77 86 81 104 87 161 51 39
Adjusted Earnings Per Share 9.1 11.8 18.6 20.7 19.6 24 20.1 37.2 11.9 9.1

Epigral Profit & Loss

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 829 1551 2188 1929 2550 2419
Other Income 7 8 9 7 15 19
Total Income 836 1559 2198 1936 2565 2438
Total Expenditure 567 1041 1499 1448 1839 1846
Operating Profit 269 518 698 488 726 591
Interest 34 48 67 73 53 68
Depreciation 74 86 109 124 133 161
Exceptional Income / Expenses 0 0 0 0 0 0
Profit Before Tax 161 383 522 291 541 363
Provision for Tax 60 131 169 95 183 23
Profit After Tax 101 253 353 196 358 338
Adjustments 0 0 0 0 0 0
Profit After Adjustments 101 253 353 196 358 338
Adjusted Earnings Per Share 24.3 60.8 85 47.1 82.9 78.3

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 32% 18% 0% 0%
Operating Profit CAGR 49% 12% 0% 0%
PAT CAGR 83% 12% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -36% 4% NA% NA%
ROE Average 23% 26% 28% 28%
ROCE Average 25% 25% 24% 24%

Epigral Balance Sheet

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 684 726 1069 1254 1905
Minority's Interest 0 0 0 0 0
Borrowings 340 768 545 547 449
Other Non-Current Liabilities 35 97 171 214 306
Total Current Liabilities 389 532 648 780 493
Total Liabilities 1449 2124 2432 2794 3152
Fixed Assets 1102 1068 1804 1767 2238
Other Non-Current Assets 165 609 209 526 139
Total Current Assets 181 447 419 502 775
Total Assets 1449 2124 2432 2794 3152

Epigral Cash Flow

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 1 25 14 3
Cash Flow from Operating Activities 229 284 626 398 441
Cash Flow from Investing Activities -197 -455 -437 -401 -262
Cash Flow from Financing Activities -32 195 -200 -8 -164
Net Cash Inflow / Outflow 1 24 -11 -11 15
Closing Cash & Cash Equivalent 1 25 14 3 19

Epigral Ratios

# Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 24.27 60.84 85.03 47.14 82.91
CEPS(Rs) 41.97 81.51 111.25 76.88 113.64
DPS(Rs) 0 0 5 5 6
Book NAV/Share(Rs) 113.88 174.72 257.3 301.83 441.48
Core EBITDA Margin(%) 30.5 31.74 29.72 24.01 26.39
EBIT Margin(%) 22.79 26.9 25.42 18.18 22.07
Pre Tax Margin(%) 18.77 23.88 22.54 14.51 20.1
PAT Margin (%) 11.77 15.75 15.24 9.77 13.28
Cash Profit Margin (%) 20.35 21.1 19.94 15.94 18.21
ROA(%) 6.96 14.15 15.51 7.5 12.03
ROE(%) 21.31 42.16 39.36 16.86 22.65
ROCE(%) 15.97 29.4 32.2 17.5 25.26
Receivable days 50.62 42.65 33.28 31.43 27.86
Inventory Days 22.99 23.66 28.81 43.24 44.12
Payable days 69.2 38.64 32.46 50.59 49.84
PER(x) 0 16.01 11.09 23.25 22.9
Price/Book(x) 0 5.57 3.67 3.63 4.3
Dividend Yield(%) 0 0 0.53 0.46 0.32
EV/Net Sales(x) 0.95 3.23 2.18 2.86 3.43
EV/Core EBITDA(x) 2.94 9.68 6.85 11.3 12.06
Net Sales Growth(%) 0 87.18 41.1 -11.84 32.19
EBIT Growth(%) 0 121.21 36.43 -38.19 63.18
PAT Growth(%) 0 150.68 39.76 -44.56 82.62
EPS Growth(%) 0 150.7 39.76 -44.56 75.89
Debt/Equity(x) 0.79 1.36 0.82 0.77 0.31
Current Ratio(x) 0.47 0.84 0.65 0.64 1.57
Quick Ratio(x) 0.33 0.55 0.32 0.31 0.79
Interest Cover(x) 5.68 8.91 8.82 4.96 11.16
Total Debt/Mcap(x) 0 0.24 0.22 0.21 0.07

Epigral Shareholding Pattern

# Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Promoter 71.38 71.38 71.49 71.58 71.58 68.94 68.95 68.83 68.83 68.83
FII 1.15 1.18 1.36 1.47 2.09 3.01 3.01 3.05 2.71 2.36
DII 0.07 0.08 0.05 0.2 1.19 4.33 4.68 4.81 4.95 5.15
Public 27.41 27.36 27.1 26.74 25.13 23.72 23.35 23.31 23.52 23.66
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Epigral News

Epigral Pros & Cons

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 26%
  • Debtor days have improved from 50.59 to 49.84days.
  • Company has reduced debt.
  • Company is almost debt free.

Cons

* The pros and cons are machine generated.

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares
whatsapp

Please Login!

Click to Login
OR
Get free Account

Error!